An open-label, randomized, two treatment, cross over, single dose study to evaluate bioequivalence between fixed-dose combination of 300/5/25 mg aliskiren/amlodipine/hydrochlorothiazide (HCTZ) tablet and free combination of market formulations of the 300 mg aliskiren, 5 mg amlodipine and 25 mg (HCTZ) in healthy subjects.

Trial Profile

An open-label, randomized, two treatment, cross over, single dose study to evaluate bioequivalence between fixed-dose combination of 300/5/25 mg aliskiren/amlodipine/hydrochlorothiazide (HCTZ) tablet and free combination of market formulations of the 300 mg aliskiren, 5 mg amlodipine and 25 mg (HCTZ) in healthy subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Aliskiren; Aliskiren/amlodipine/hydrochlorothiazide; Amlodipine; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 08 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top